ERBB3 G284R
|
Urothelial Cancer
|
ERBB3 G284R
|
Urothelial Cancer
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
ERBB3 G284R
|
HER2 Negative Breast Cancer
|
ERBB3 G284R
|
HER2 Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: C4 – Case Studies
|
trastuzumab + lapatinib Sensitive: C4 – Case Studies
|